In patients with intermediate cardiovascular risk and impaired renal function, choosing the appropriate risk assessment strategy requires balancing diagnostic accuracy with renal safety (i.e., avoiding contrast-induced nephropathy).
In patients with intermediate cardiovascular risk and impaired renal function, choosing the appropriate risk assessment strategy requires balancing diagnostic accuracy with renal safety (i.e., avoiding contrast-induced nephropathy).
Recommended approach:
1. Start with non-contrast tools:
• CAC Score (Coronary Artery Calcium) via non-contrast cardiac CT is safe in CKD stages 2–3 and provides strong negative predictive value.
• If CAC = 0, the patient may be reclassified to low risk, avoiding unnecessary therapy.
• If CAC >0, especially >100, intensification of preventive measures (e.g. statins) is often warranted.
2. Avoid contrast-enhanced CT angiography (CCTA):
• Generally avoided in patients with eGFR < 30 mL/min/1.73 m² unless clinically essential and hydration protocols can be applied.
3. Use biomarkers and clinical scores:
• SCORE2 or ASCVD Risk Estimator Plus (without imaging) may guide initial decisions.
• hs-CRP, lipoprotein(a), or ApoB may add value in selected cases.
4. Carotid ultrasound:
• A practical, contrast-free tool to assess subclinical atherosclerosis in high-risk individuals.
• Detection of carotid plaques can reclassify a patient’s risk upwards.
5. Emerging role of PET/MRI or MR vessel wall imaging:
• Research-based for now, but may offer future non-nephrotoxic options for plaque characterization.
⸻
Conclusion:
For a patient with moderate cardiovascular risk and impaired renal function, CAC scoring remains the best validated and safest imaging option. Carotid ultrasound is a valuable adjunct, and combining clinical scores with imaging helps refine decisions without harming kidney function.
